European regulators have ordered the removal of all medications containing levamisole from the market, citing concerns over a rare but serious neurological side effect. The decision, announced on February 15, 2026, by the European Medicines Agency (EMA), impacts drugs primarily used to treat parasitic worm infections. This action follows a comprehensive safety review and underscores the importance of continually assessing the benefit-risk profile of medications, even those long-established.
The EMA’s safety committee, known as the Pharmacovigilance Risk Assessment Committee (PRAC), determined that the benefits of levamisole no longer outweigh the risks. Specifically, the committee linked the drug to leucoencephalopathy, a severe and uncommon condition affecting the brain’s white matter. The PRAC’s recommendation applies to all levamisole-containing medicines authorized for employ within the European Union. More details on the EMA’s decision can be found on their website.
What Medications are Affected?
The withdrawal impacts several types of medications, including antelmintic drugs – those used to treat intestinal parasitic worms – and systemic antiparasitic medications used for milder infections. Crucially, the action applies to products containing levamisole as a single active ingredient for human use. These are typically prescribed for relatively common, non-life-threatening conditions where safer alternative treatments are now available.
Specifically, the affected medications include:
- Anthelmintic drugs (for intestinal worm infections)
- Systemic antiparasitic medicines for mild infections
- Levamisole-based products used in monoterapia (single-drug therapy) for humans
Understanding the Risks of Leucoencephalopathy
Leucoencephalopathy is a rare but potentially devastating neurological condition. According to the EMA, symptoms can emerge even after a single dose of levamisole, and may manifest anywhere from one day to several months after treatment concludes. The PRAC’s review did not identify any strategies to effectively mitigate the risk, nor were specific patient populations found to be more susceptible. No safe usage patterns for levamisole were established.
The unpredictable nature of the adverse effect and the lack of identified risk-reduction strategies led the PRAC to conclude that the overall benefit-risk balance was unfavorable. This determination prompted the recommendation for complete market withdrawal.
What Happens Next?
All medications containing levamisole will be removed from circulation throughout the European Union. The PRAC has also issued a Direct Healthcare Professional Communication (DHPC) to inform physicians, pharmacists, and other healthcare providers about the risk of leucoencephalopathy and the decision to withdraw the drug. This communication will be disseminated through marketing authorization holders and published in national health registers across EU member states.
The EMA’s action serves as a reminder of the rigorous safety monitoring processes in place for pharmaceuticals. Although levamisole has been used for decades to treat parasitic infections, the identification of this serious neurological risk necessitated a decisive response to protect public health. The EMA website will continue to provide updates on this and other safety concerns.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have questions or concerns about this developing story? Share your thoughts in the comments below, and please share this article with anyone who may be affected.
